Rubius Therapeutics Past Earnings Performance
Past criteria checks 0/6
Rubius Therapeutics has been growing earnings at an average annual rate of 8.6%, while the Biotechs industry saw earnings growing at 17.8% annually.
Key information
8.6%
Earnings growth rate
11.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -1,187.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03
Aug 09Rubius: Poor Data, Punishing Environment, Beaten Stock
Jun 19Rubius Looks Attractive Before AACR Data Readout
Mar 21Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?
Oct 28
Our Read On Rubius Therapeutics
Jul 11Rubius Therapeutics EPS beats by $0.02
May 10Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?
Feb 25Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow
Jan 14Rubius Therapeutics EPS misses by $0.01
Nov 09Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers
Oct 28Revenue & Expenses Breakdown
How Rubius Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -180 | 31 | 96 |
| 30 Sep 22 | 0 | -215 | 44 | 135 |
| 30 Jun 22 | 0 | -201 | 48 | 149 |
| 31 Mar 22 | 0 | -207 | 52 | 152 |
| 31 Dec 21 | 0 | -197 | 53 | 142 |
| 30 Sep 21 | 0 | -182 | 53 | 127 |
| 30 Jun 21 | 0 | -174 | 53 | 118 |
| 31 Mar 21 | 0 | -162 | 51 | 108 |
| 31 Dec 20 | 0 | -168 | 50 | 116 |
| 30 Sep 20 | 0 | -172 | 51 | 121 |
| 30 Jun 20 | 0 | -178 | 54 | 126 |
| 31 Mar 20 | 0 | -179 | 56 | 128 |
| 31 Dec 19 | 0 | -163 | 57 | 112 |
| 30 Sep 19 | 0 | -146 | 55 | 98 |
| 30 Jun 19 | 0 | -126 | 53 | 79 |
| 31 Mar 19 | 0 | -107 | 48 | 63 |
| 31 Dec 18 | 0 | -89 | 40 | 52 |
| 30 Sep 18 | 0 | -80 | 38 | 42 |
| 30 Jun 18 | 0 | -65 | 31 | 34 |
| 31 Mar 18 | 0 | -54 | 26 | 27 |
| 31 Dec 17 | 0 | -45 | 22 | 21 |
Quality Earnings: RUBY is currently unprofitable.
Growing Profit Margin: RUBY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if RUBY's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare RUBY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RUBY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: RUBY has a negative Return on Equity (-1187.4%), as it is currently unprofitable.